Investing.com - Biondvax Pharma ADR reported on Monday fourth quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Biondvax Pharma ADR announced earnings per share of ₪-0.085 on revenue of ₪0.00. Analysts polled by Investing.com anticipated EPS of ₪-0.16 on revenue of ₪0.00.
Biondvax Pharma ADR shares are down 26.17% from the beginning of the year, still down 58.39% from its 52 week high of ₪4.17 set on July 28, 2021. They are under-performing the Nasdaq which is down 9.55% from the start of the year.
Biondvax Pharma ADR shares lost 2.53% in intra-day trade following the report.
Biondvax Pharma ADR follows other major Healthcare sector earnings this month
Biondvax Pharma ADR's report follows an earnings missed by Merck ADR on March 3, who reported EPS of ₪0.4558 on revenue of ₪5.77B, compared to forecasts EPS of ₪0.4818 on revenue of ₪5.88B.
Bayer AG PK had beat expectations on March 1 with first quarter EPS of ₪0.351 on revenue of ₪12.39B, compared to forecast for EPS of ₪0.2821 on revenue of ₪12.04B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar